Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol

• Register: ChiCTR
• Last refreshed on: 30 April 2019
• Main ID: ChiCTR1900021760
• Date of registration: 2019-03-08
• Prospective Registration: Yes
• Primary sponsor: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
• Public title: Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol
• Scientific title: Effect-site concentration of remifentanil for I-gel insertion in male patients with Parkinson’s disease undergoing deep brain stimulator implantation during target-controlled infusion of propofol
• Date of first enrolment: 2019-03-09
• Target sample size: Parkinson’s disease:25;Non-Parkinson’s disease:25;
• Recruitment status: Recruiting
• URL: http://www.chictr.org.cn/showproj.aspx?proj=36620
• Study type: Observational study
• Study design: Factorial
• Phase: N/A

Countries of recruitment

China

Contacts

• Name: Chengwei Yang
• Affiliation: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

• Name: Juan Li
• Affiliation: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China

Key inclusion & exclusion criteria

Inclusion criteria: 1. PD patients undergoing DBS insertion and pulse generator placement or non-PD patients undergoing intracranial surgery
2. Aged 40-64 years;
3. male.
Exclusion criteria: 1. An ASA score higher than class III;
2. BMI>30kg/m2;
3. predicted difficult airway;
4. alcohol or drug abusers;
5. reactive airway disease or signs of upper respiratory infection;
6. patients who have a high risk of gastric aspiration upon anaesthesia induction.

Age minimum: 40
Age maximum: 64
Gender: Male

Health Condition(s) or Problem(s) studied

Parkinson’s disease

Intervention(s)

Parkinson’s disease:propofol and remifentanil;Non-Parkinson’s disease:propofol and remifentanil;

Primary Outcome(s)

Median effective effect-site concentration of remifentanil for I-gel insertion;

Secondary Outcome(s)

Heart rate;Mean arterial pressure;BIS;

Source(s) of Monetary Support

Natural Science Foundation of Anhui Province of China

Ethics review

Status: Approved
Approval date: 08/12/2018
Contact:

Chen Meinan